🏛️ Verified NIH Record • Updated 2026-01-12
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors (NCT06859762)
A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL217 in Patients With Advanced Solid Tumors
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
🩺 Plain-English Summary (8th-Grade Level)
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Mayo Clinic Arizona — Phoenix, Arizona
- UCLA Hematology/Oncology - Santa Monica — Santa Monica, California
- Yale Cancer Center — New Haven, Connecticut
- The University of Kansas Cancer Center (KUCC) — Kansas City, Kansas
- University of Maryland Medical Center-Greenebaum Cancer Ctr - Medical Oncology — Baltimore, Maryland
- Karmanos Cancer Institute — Detroit, Michigan
- Columbia University Irving Medical Center — New York, New York
- Duke University Medical Center (DUMC) — Durham, North Carolina
- University of Cincinnati Medical Center — Cincinnati, Ohio
- Cleveland Clinic Taussig Cancer Institute — Cleveland, Ohio
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- UT Health San Antonio - Mays Cancer Center — San Antonio, Texas
- University of Wisconsin Health - UW Carbone Cancer Center — Madison, Wisconsin
- Peking Union Medical College Hospital — Beijing, Bejing
- Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
- Cancer Hospital of Shandong First Medical University — Jinan, Shandong
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine — Shanghai, Shanghai Municipality
- Tianjin Medical University Cancer Institute & Hospital — Tianjin, Tianjin Municipality
- Zhejiang Cancer Hospital — Hangzhou, Zhejiang
📞 Contact the Study Coordinator
Phone: +86 0512-62858368
Email: clinicaltrials@medilinkthera.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.